The best predictor of kallistatin was HbA1c in T2D patients, high-sensitivity C-reactive protein (hsCRP) and betatrophin in NDO patients, and hsCRP in controls. This evidence concerns the gene ANGPTL8 and type 2 diabetes mellitus.